68Ga-PSMA-11 PET-directed Radioligand Therapy in Metastatic Hepatocellular Carcinoma (HCC)

Part of paid clinical trials in Cleveland, Ohio.

Sponsor
Melissa Lumish
Study ID
NCT06852820
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Lu-PSMA-617 — DRUG
    Given IV

Study Details

The purpose of this study is to look at the effects (good and bad) of a drug called 177Lu-PSMA-617 (also known as the study drug) when given to participants who have prostate specific membrane antigen (PSMA) positive liver cancer.

Key Dates

Start date
Jun 30, 2026
Status verified
May 2026
Primary completion
Dec 1, 2026
Completion
Apr 1, 2027

Study Design

Enrollment
10 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Lu-PSMA-617
    Participants will receive 177Lu-PSMA-617 7.4 GBq (200 mCi) once every 6 weeks. 177Lu-PSMA-617 is a radiopharmaceutical which will be administered intravenously (IV).

Primary Outcome Measure

Percentage of Participants with PSMA-Avid Lesions on PET Imaging (≥50%) [ Time Frame: 12 weeks post intervention ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Case Comprehensive Cancer Center, University Hospitals Cleveland Medical Center, Seidman Cancer CenterClevelandOhio44106
Melissa Lumish, MD
[email protected]
216-844-3951

Find similar trials in Cleveland, OH

By condition
Liver cancer
By specialty
OncologyGI oncologyHepatology
By research site
Case Comprehensive Cancer Center, University Hospitals Cleveland Medical Center, Seidman Cancer Center· Cleveland, OH

Related Studies